Skip to main content

Aditxt, Inc.

corporate_fare Company Profile

Aditxt, Inc.

ADTX·OTC·Life Sciences·CIK 0001726711

The company, incorporated in Delaware on September 28, 2017, and headquartered in Mountain View, California, focuses on redefining how health innovations are discovered, developed, and deployed. Its mission is to transform a centralized industry into a socially owned and guided ecosystem to advance human well-being by engaging stakeholders in all aspects of innovation. Initially, the company focused on an immune modulation technology called ADI/Adimune, aimed at prolonging and enhancing the life quality of organ transplant patients. Since then, it has expanded its portfolio of innovations and subsidiaries and continues to evaluate various promising health innovations. In January 2023, the subsidiary Adimune™, Inc. was formed to lead the company's immune modulation therapeutic programs. Adimune's proprietary product, Apoptotic DNA Immunotherapy™ (ADI™), uses a novel approach that mimics the body's natural tolerance induction to its own tissues. It consists of two DNA molecules designed to deliver signals to induce tolerance. ADI-100, the first product candidate from the ADI platform, is designed to tolerize against glutamic acid decarboxylase ("GAD"), an antigen implicated in type-1 diabetes (T1D), psoriasis, and many autoimmune diseases of the CNS. ADI-100 has been successfully tested in several preclinical models, including skin grafting, psoriasis, and T1D. All preclinical studies for ADI-100 are complete, providing data supporting its potential effectiveness in restoring durable tolerance, as shown in 10-month studies for preventing and treating T1D in nonclinical animal models.

Aditxt, Inc. (OTC:ADTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 44 items for ADTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-15, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 16 rated 8 or above. Recent SEC coverage for ADTX spans 8-K, 4, PRE 14A.

Recent high-impact activity:

  • Aditxt's Ignite Proteomics SPAC Merger Collapses as Parties Mutually Terminate Deal
  • Aditxt Confirms Nasdaq Form 25 Filing — Delisting Becomes Effective Within Days
  • Aditxt Divests Pearsanta for Contingent Royalties and Milestones
  • Aditxt Restructures Note Agreement, Adds New Investor Amid Nasdaq Delisting
  • Nasdaq Panel Denies Aditxt's Listing Request; Trading Suspension Imminent

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.19K
Net Income
-$43.1M
Diluted EPS
-$1153.83
Op. Cash Flow
-$25.69M
Free Cash Flow
-$25.7M
Gross Profit
$268
Operating Income
-$19.57M
Cash & Equivalents
$3.2M
Debt / Equity
0.00×
Net Margin
-13490.28×
Shares Outstanding
411.5K sh
Source: 10-K · filed 2026-03-31 · accession 0001213900-26-037529

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 896,756 shares in ADTX as of the October 30, 2026 settlement, a 0.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 3.3% of ADTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)896,756 shares as of October 30, 2026
Change vs prior period▼ 0.1%
Days to cover1.00 at avg daily volume of 2,005,755
Daily short volume (FINRA facilities)3.3% of 310,423 shares on November 20, 2026
5-day average short volume42.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ADTX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-23.

Additional Capital Raise · Increased Convertible Note Debt

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →

No longer listed

ADTX (Aditxt, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed ADTX - Latest Insights

ADTX
Oct 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
ADTX
Sep 23, 2026, 11:34 AM EDT
Filing Type: 8-K
Importance Score:
8
ADTX
Aug 19, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
ADTX
Jul 17, 2026, 12:06 PM EDT
Filing Type: 8-K
Importance Score:
7
ADTX
Jun 24, 2026, 11:36 AM EDT
Filing Type: 8-K
Importance Score:
10
ADTX
Jun 24, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
ADTX
Jun 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
9
ADTX
Jun 23, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
Jun 23, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
ADTX
Jun 22, 2026, 9:36 PM EDT
Source: Wiseek News
Importance Score:
7
ADTX
Jun 16, 2026, 9:14 AM EDT
Filing Type: 4
Importance Score:
9
ADTX
Jun 11, 2026, 3:09 PM EDT
Filing Type: 4
Importance Score:
7
ADTX
Jun 10, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
10
ADTX
Jun 10, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
ADTX
Jun 09, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
ADTX
Jun 09, 2026, 7:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
ADTX
Jun 05, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
Jun 01, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 29, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 22, 2026, 5:03 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets